Researchers and clinician researchers are invited to submit Expressions of Interest to access the resources of the THINK Advanced Therapeutics Pipeline Program and discover how to identify exciting novel biology that can be translated into new therapeutics for childhood illnesses.

Led by A/Prof Greg Arndt, Head of the Australian Cancer Research Foundation (ACRF) Drug Discovery Centre at Children’s Cancer Institute, THINK is part of the Enabling Platforms Program funded by Luminesce Alliance.

The Luminesce Alliance paediatric precision medicine Enabling Platforms are functional specialisations that cross disease areas and Luminesce Alliance member organisations.

The platforms provide support for leading clinicians and researchers to better understand and apply precision medicine.

One of five platforms, the Precision Therapy Enabling Platform is designed to provide a pipeline that bridges the gap between scientific discovery and the development of new drugs for patients.

This Platform has two streams, one of which is the THerapeutic INnovations for Kids (THINK) program, which focuses on discovering and developing novel therapeutics for childhood cancers, genetic diseases, and neurodevelopmental disorders.

THINK was formed within Children’s Cancer Institute to accelerate the development and delivery of new treatments for children with cancer. This program is a disease-agnostic integrated pipeline of technologies, capabilities, and expertise that spans all stages of the drug discovery and development pathway.

The overarching aim of the THINK program within the Luminesce Alliance Advanced Therapeutics Pipeline is to extend the THINK project portfolio to include not only cancer, but also new projects in rare genetic diseases and neurodevelopmental disorders.

To find out more, including how to register, click here.